LXEO

Over the past six months, Lexeo Therapeutics' stock price has fluctuated, with a 52-week high of $10.99 on December 22, 2025, and a 52-week low of $3.46 on September 22, 2026. The stock price was $4.76 on September 8, 2026, and $3.50 on September 22, 2026. Key events impacting the stock include the reporting of fourth quarter and full year 2025 financial results in March 2026, which highlighted progress in its cardiac pipeline and positive interim clinical data for LX2020 and LX2006, along with discussions with the FDA. In August 2026, the company reported its second quarter 2026 financial results and operational highlights. In September 2026, Lexeo Therapeutics announced strategic transactions to expand its presence in Friedreich's ataxia, including the acquisition of Mantle Therapeutics Inc. and new research collaborations, and also participated in investor conferences.